Sickle cell disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• G6PD 0
• NLRP3 0
• APOL1 0
• CD19 3
• BTK 0
• FGFR 0
• NRF2 0
• SGLT2 1
• CFTR 1
• CXCR4 0
• DMD 1
• GLP-1 0
• HDAC 1
• HMGB1 0
• HTT 1
• JAK 0
• NF1 1
• SMN1 1

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH OD · C06

  BRF: LLU Cellular Therapy Research Facility

  Loma Linda University· Loma Linda, United States· US$8,000,000 awarded in fiscal year 2026· until Jan 2028

• NIH NHLBI · K24

  Translational Research in Sleep and Circadian Rhythms

  University of Alabama at Birmingham· Birmingham, United States· US$71,934 awarded in fiscal year 2026· until May 2031

• NIH FIC · R21

  Mobile Optical System for Stroke Risk Screening in Pediatric Sickle Cell Disease in Uganda

  Kennesaw State University· Kennesaw, United States· US$179,988 awarded in fiscal year 2026· until Jun 2028

• NIH NHLBI · K01

  Healthcare Stressors and Biobehavioral Stress Responses in Sickle Cell Disease: An Investigation of AYA and Clinical Factors

  Children's Hosp of Philadelphia· Philadelphia, United States· US$168,156 awarded in fiscal year 2026· until Aug 2031

• NIH NHLBI · R03

  Dissecting von Willebrand factor secretory machinery for therapeutic vulnerabilities

  Yale University· New Haven, United States· US$252,000 awarded in fiscal year 2026· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Innovating Sickle Cell Disease Treatment: From Non-Canonical Signaling and Immune Activation to Personalized Targeted Therapies (TARGET-SCD)

  Universite Paris Cite· Paris, France· EU contribution €2,449,320· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Deciphering Inflammatory and Placental Mechanisms of Pre-eclampsia in Sickle Cell Disease (PRECISE)

  Imagine Institut des Maladies Genetiques Necker Enfants Malades Fondation· Paris, France· EU contribution €242,261· until Dec 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  A metabolic-based defense strategy against malaria (KILLBILL)

  Fundacao Gimm - Gulbenkian Institute for Molecular Medicine· Lisboa, Portugal· EU contribution €2,500,000· until Sept 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-CSA

  CONSORTIUM FOR DEVELOPING REGULATORY CAPACITY FOR CLINICAL TRIALS USING GENE THERAPY PRODUCTS AND STRENGTHENING PHARMACOVIGILANCE IN THE CONDUCT OF CLINICAL TRIALS IN EAST AFRICA (CAPACITY 2023)

  Universidade de Coimbra· Coimbra, Portugal· EU contribution €999,315· until Mar 2027· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Synthetic generation of hematological data over federated computing frameworks (SYNTHEMA)

  Universidad Politecnica de Madrid· Madrid, Spain· EU contribution €6,514,560· until Nov 2026· 10 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 348 running projects, newest first. Listed amounts together: US$215.2m + €25.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• CRISPR-Cas Systems 15
• Gene Expression Profiling 7
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 2
• Mass Spectrometry 2
• Flow Cytometry 5
• Immunohistochemistry 2
• Magnetic Resonance Imaging 21
• Machine Learning 5
• Deep Learning 3
• Cohort Studies 19
• Genome-Wide Association Study 5

• Antibiotic Choice for Community-Acquired Pneumonia in Children With Medical Complexity.

  Pediatrics, Nov 2026

• Identification of predictive factors for reversal of cerebral vasculopathy in an original longitudinal cohort study in newborns with sickle cell anaemia.

  Br J Haematol, Aug 2026

• Low Prevalence of the HBB c.20A > T (HbS) Allele in a Turkish Cypriot Cohort: A Molecular Screening Study.

  Hemoglobin, Aug 2026

• Asthma and overt stroke in children with sickle cell disease: a multicenter pediatric cohort study in French Guiana.

  BMC Pediatr, Jul 2026

• Accurate identification of sickle cell disease cases in a large genotyped cohort using electronic health record data.

  Blood Adv, Jun 2026

• Hematopoietic Stem Cell Transplant and Brain Volume Changes in Adults With Sickle Cell Disease.

  Neurology, May 2026

• Changes in circular RNA expression in acute chest syndrome and vaso-occlusive crisis in sickle cell disease: analysis of a public RNA-seq cohort.

  Expert Rev Hematol, May 2026

• Persistent proteinuria among a cohort of Nigerian children with sickle cell anaemia.

  PLoS One, Apr 2026

• Renal complications in pediatric sickle cell disease: results from a single-center study.

  Ann Hematol, Apr 2026

• The Role of Platelet-to-Neutrophil Ratio as a Biomarker for Pulmonary Hypertension in Sickle Cell Disease Patients: A Retrospective Cohort Study.

  Medicina (Kaunas), Apr 2026

See which targets of this disease your abstract mentions, and go to the people working on them.